COST EFFECTIVENESS OF EVEROLIMUS FOR SECOND LINE TREATMENT OF METASTATIC RENAL CELL CANCER IN SERBIA

被引：0
|
作者：
Mihajlovic, J. [1 ]
Pechlivanoglou, P. [1 ]
Sabo, A. [2 ]
Tomic, Z. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Univ Novi Sad, Fac Med, Novi Sad 21000, Serbia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2141
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
  • [22] Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
    Geczi, Lajos
    Bodoky, Gyorgy
    Rokszin, Gyorgy
    Fabian, Ibolya
    Torday, Laszlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2201 - 2207
  • [23] Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E557 - E562
  • [24] Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms
    Rothermundt, C.
    von Rappard, J.
    Eisen, T.
    Escudier, B.
    Gruenwald, V.
    Larkin, J.
    McDermott, D.
    Oldenburg, J.
    Porta, C.
    Rini, B.
    Schmidinger, M.
    Sternberg, C. N.
    Putora, P. M.
    WORLD JOURNAL OF UROLOGY, 2017, 35 (04) : 641 - 648
  • [25] Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms
    C. Rothermundt
    J. von Rappard
    T. Eisen
    B. Escudier
    V. Grünwald
    J. Larkin
    D. McDermott
    J. Oldenburg
    C. Porta
    B. Rini
    M. Schmidinger
    C. N. Sternberg
    P. M. Putora
    World Journal of Urology, 2017, 35 : 641 - 648
  • [26] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Nunez, S. M.
    Godoy, J., I
    Cardona, A. F.
    Otero, J. M.
    Lujan, M.
    Lopera, D.
    Carranza, H.
    Spath, A.
    Gis, P. R.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [27] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Does First-line Treatment Impact the Cost Effectiveness of Second-line Treatment for Elderly Metastatic Colon Cancer Patients?
    Mullins, C.
    Woldemichael, A.
    Zheng, Z.
    Onukwugha, E.
    Seal, B. S.
    Hanna, N.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S141 - S141
  • [29] Second-line treatment for renal cell cancer
    Di Lorenzo, G.
    De Placido, S.
    Buonerba, C.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 617 - 618
  • [30] Second-line treatment for renal cell cancer
    G Di Lorenzo
    S De Placido
    C Buonerba
    British Journal of Cancer, 2012, 106 : 617 - 618
12345